Cantitate/Preț
Produs
Total produse
Vezi coșul
Resistance to Ibritumomab in Lymphoma de Makoto Hosono

Resistance to Ibritumomab in Lymphoma: Resistance to Targeted Anti-Cancer Therapeutics, cartea 18

Editat de Makoto Hosono, Jean-François Chatal
en Limba Engleză Hardback – 7 mai 2018
This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 68884 lei  6-8 săpt.
  Springer International Publishing – 8 ian 2019 68884 lei  6-8 săpt.
Hardback (1) 69542 lei  6-8 săpt.
  Springer International Publishing – 7 mai 2018 69542 lei  6-8 săpt.

Din seria Resistance to Targeted Anti-Cancer Therapeutics

  • 5% Current Applications for Overcoming Resistance to Targeted Therapies
    Preț: 69754 lei
  • 5% Resistance to Proteasome Inhibitors in Cancer: Molecular Mechanisms and Strategies to Overcome Resistance
    Preț: 107543 lei
  • 5% Resistance to Tyrosine Kinase Inhibitors
    Preț: 106464 lei
  • 5% Resistance to Targeted Therapies Against Adult Brain Cancers
    Preț: 106870 lei
  • 5% Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance
    Preț: 106197 lei
  • 5% TRAIL, Fas Ligand, TNF and TLR3 in Cancer
    Preț: 107157 lei
  • 5% Resistance to Molecular Therapies for Hepatocellular Carcinoma
    Preț: 106248 lei
  • 5% Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
    Preț: 106782 lei
  • 5% Resistance to Targeted Therapies in Breast Cancer
    Preț: 106464 lei
  • 5% Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
    Preț: 81690 lei
  • 5% Cancer Stem Cell Resistance to Targeted Therapy
    Preț: 69437 lei
  • 5% Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance
    Preț: 106248 lei
  • 5% Resistance to Targeted Therapies in Lymphomas
    Preț: 69186 lei
  • 5% Resistance to Targeted Therapies in Multiple Myeloma
    Preț: 99519 lei
  • 5% Resistance to Targeted ABC Transporters in Cancer
    Preț: 70285 lei
  • 5% Resistance to Photodynamic Therapy in Cancer
    Preț: 70055 lei
  • 5% Resistance to Immunotoxins in Cancer Therapy
    Preț: 70055 lei
  • 5% Resistance of Cancer Cells to CTL-Mediated Immunotherapy
    Preț: 70586 lei
  • 5% Resistance to Aromatase Inhibitors in Breast Cancer
    Preț: 70250 lei
  • 5% Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy
    Preț: 69718 lei

Preț: 69542 lei

Preț vechi: 73202 lei
-5% Nou

Puncte Express: 1043
Preț estimativ în valută:
13310€ • 13873$ • 11080£

Carte tipărită la comandă

Livrare economică 07-21 ianuarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319782379
ISBN-10: 3319782371
Pagini: 240
Ilustrații: XIII, 158 p. 18 illus., 14 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.42 kg
Ediția:1st ed. 2018
Editura: Springer International Publishing
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics

Locul publicării:Cham, Switzerland

Cuprins

Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma.- Biology and Pathology of B-cell lymphoma.- Resistance to Y-90 Ibritumomab Tiuxetan Therapy.- Features of Ibritumomab as Radionuclide Therapy.- Radiological Evaluation of Response and Resistance of Ibritumomab.- Characteristics of Ibritumomab as Radionuclide Therapy Agent.- Resistance and Heterogeneity of Intratumoral Antibody Distribution.- Radiation Dosimetry in Ibritumomab Therapy.- Combining RAIT and immune-based therapies to overcome resistance in cancer?.- Prospects for enhancing efficacy of radioimmunotherapy.- Index.

Notă biografică

Makoto Hosono, MD, PhD, is a Professor of Radiology and Nuclear Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Japan, and serves as a member of Committee 3, International Commission on Radiological Protection. 


Jean-François Chatal, MD, PhD, is an Emeritus Professor of Nuclear Medicine at the University of Nantes, France. He is one of the international leaders who developed radioimmunotherapy, that is, therapy using radiolabeled anti-tumor antibodies. He created and headed an INSERM  research laboratory and also initiated the installation of a cyclotron institute termed ARRONAX for the production of novel radionuclides for nuclear medicine.

Textul de pe ultima copertă

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

Caracteristici

This book features chapters written by internationally known experts in the field This book will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects and medical physics that deals with radiation dosimetry This book will provide future prospects for overcoming resistance and enhancing the efficacy of Ibritumomab